Globe News Wire
22 Jul 2026, 20:30 UTC · 6w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
Serina Therapeutics has appointed Farrell Simon, an executive with a track record of raising over $400 million in capital at Trevi Therapeutics, to its Board of Directors. — The addition of a director specifically cited for his expertise in capital raising and investor engagement suggests a strategic move to strengthen the company's funding capabilities.
+0.30The company is conducting a Phase 1b registrational study for SER-252, a treatment for Parkinson’s disease and motor fluctuations. — Clinical progress of a lead asset is a primary driver of value for clinical-stage biotech companies.
+0.20Which stocks this story touches
The company appointed a highly experienced pharmaceutical executive to its Board of Directors.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2d ago
